Literature DB >> 12126895

Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine.

Yoshitsugu Kojima1, Ke-Qin Xin, Takaaki Ooki, Kenji Hamajima, Tomohiro Oikawa, Kaori Shinoda, Tomomi Ozaki, Yuka Hoshino, Nao Jounai, Masatoshi Nakazawa, Dennis Klinman, Kenji Okuda.   

Abstract

Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs trigger an immune response characterized by the activation of B cells, NK cells and monocytes/macrophages. Based on evidence that the immunogenicity of DNA vaccines can be augmented by the addition of CpG motifs, 5-20 additional CpG motifs were cloned into a pUC-derived plasmid. Treating bone-marrow derived dendritic cells (BM-DCs) with CpG-enriched plasmids in vitro boosted their expressions of MHC class II molecules, the CD40 and CD86 activation markers. Co-administering the CpG-enriched plasmids with a DNA vaccine encoding the envelope glycoprotein of HIV to BALB/c mice significantly increased HIV-specific cell mediated and humoral immunity. A significant boost was observed when the CpG plasmid was administered either 2 or 4 days after DNA vaccination. Plasmids containing 20 CpG copies were the most effective immune enhancers both in vitro and in vivo. These results suggest that plasmids containing multiple CpG motifs may improve the immunogenicity of DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126895     DOI: 10.1016/s0264-410x(02)00238-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

Review 1.  Physical trauma of vaccination acts as a wake-up call to dangers in the skin.

Authors:  Fiona J Culley; Wieslawa Olszewska
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

Review 2.  Immune-based therapies: an adjunct to antiretroviral treatment.

Authors:  Jeffrey M Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

Review 3.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

4.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

Review 5.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

6.  Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines.

Authors:  Yun-Zhou Yu; Yao Ma; Wen-Hui Xu; Shuang Wang; Zhi-Wei Sun
Journal:  Med Microbiol Immunol       Date:  2014-09-30       Impact factor: 3.402

7.  Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene.

Authors:  So Young Choi; You Suk Suh; Jae Ho Cho; Hyun Tak Jin; Jun Chang; Young Chul Sung
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

8.  Evaluation of protective effect of multi-epitope DNA vaccine encoding six antigen segments of Toxoplasma gondii in mice.

Authors:  Shan Liu; Lin Shi; Yan-bin Cheng; Gui-xiang Fan; Hui-xun Ren; Yu-kang Yuan
Journal:  Parasitol Res       Date:  2009-03-14       Impact factor: 2.289

9.  TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine.

Authors:  Shawn Babiuk; Neeloffer Mookherjee; Reno Pontarollo; Phillip Griebel; Sylvia van Drunen Littel-van den Hurk; Rolf Hecker; Lorne Babiuk
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

Review 10.  Therapeutic HPV DNA vaccines.

Authors:  Ken Lin; Elena Roosinovich; Barbara Ma; Chien-Fu Hung; T-C Wu
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.